Key Laboratory of Biosafety, National Health Commissions, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, 102206, China.
Department of Clinical Laboratory, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Hubei Province, Xiangyang, 441021, China; Key Laboratory of Molecular Medicine, Medical College, Hubei University of Arts and Science, Xiangyang, 441053, China.
Antiviral Res. 2020 Jan;173:104646. doi: 10.1016/j.antiviral.2019.104646. Epub 2019 Nov 6.
Human coronaviruses (HCoVs) are important pathogens that cause upper respiratory tract infections and have neuroinvasive abilities; however, little is known about the dynamic infection process of CoVs in vivo, and there are currently no specific antiviral drugs to prevent or treat HCoV infection. Here, we verified the replication ability and pathogenicity of a reporter HCoV-OC43 strain expressing Renilla luciferase (Rluc; rOC43-ns2DelRluc) in mice with different genetic backgrounds (C57BL/6 and BALB/c). Additionally, we monitored the spatial and temporal progression of HCoV-OC43 through the central nervous system (CNS) of live BALB/c mice after intranasal or intracerebral inoculation with rOC43-ns2DelRluc. We found that rOC43-ns2DelRluc was fatal to suckling mice after intranasal inoculation, and that viral titers and Rluc expression were detected in the brains and spinal cords of mice infected with rOC43-ns2DelRluc. Moreover, viral replication was initially observed in the brain by non-invasive bioluminescence imaging before the infection spread to the spinal cord of BALB/c mice, consistent with its tropism in the CNS. Furthermore, the Rluc readout correlated with the HCoV replication ability and protein expression, which allowed quantification of antiviral activity in live mice. Additionally, we validated that chloroquine strongly inhibited rOC43-ns2DelRluc replication in vivo. These results provide new insights into the temporal and spatial dissemination of HCoV-OC43 in the CNS, and our methods provide an extremely sensitive platform for evaluating the efficacy of antiviral therapies to treat neuroinvasive HCoVs in live mice.
人冠状病毒(HCoVs)是引起上呼吸道感染并具有神经侵袭能力的重要病原体;然而,目前对于冠状病毒在体内的动态感染过程知之甚少,并且目前没有专门的抗病毒药物来预防或治疗 HCoV 感染。在这里,我们验证了表达 Renilla 荧光素酶(Rluc;rOC43-ns2DelRluc)的报告人冠状病毒 OC43 株在具有不同遗传背景的小鼠(C57BL/6 和 BALB/c)中的复制能力和致病性。此外,我们监测了经鼻腔或脑内接种 rOC43-ns2DelRluc 后,活的 BALB/c 小鼠体内 HCoV-OC43 通过中枢神经系统(CNS)的时空进展。我们发现 rOC43-ns2DelRluc 在经鼻腔接种后对乳鼠致命,并且在感染 rOC43-ns2DelRluc 的小鼠的大脑和脊髓中检测到病毒滴度和 Rluc 表达。此外,通过非侵入性生物发光成像在感染传播到 BALB/c 小鼠的脊髓之前,首先在大脑中观察到病毒复制,这与其在中枢神经系统中的嗜性一致。此外,Rluc 读数与 HCoV 复制能力和蛋白表达相关,允许在活鼠中定量评估抗病毒活性。此外,我们验证了氯喹强烈抑制 rOC43-ns2DelRluc 在体内的复制。这些结果提供了关于 HCoV-OC43 在中枢神经系统中的时空传播的新见解,并且我们的方法为评估在活鼠中治疗神经侵袭性 HCoV 的抗病毒疗法的疗效提供了一个极其敏感的平台。